Blees Niels R, Teunissen Michelle, Dobenecker Britta, Prawitt Janne, Tryfonidou Marianna A, Jan Corbee Ronald
Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.
Department of Animal Sciences, Chair of Animal Nutrition and Dietetics, Ludwig-Maximilians-Universität Munich, Oberschleissheim, Germany.
J Anim Physiol Anim Nutr (Berl). 2025 Mar;109(2):590-600. doi: 10.1111/jpn.14076. Epub 2024 Nov 27.
Osteoarthritis (OA) is a common disease in dogs with severe impact on their welfare. The multimodal management of OA includes feeding therapeutic diets and nutraceuticals to slow down OA progression. Collagen hydrolysates (CH) are a nutritional supplement that may exert anabolic effects on osteoarthritic joint cartilage as well as disease-modifying effects. After oral intake, CH is absorbed, mainly as amino acids, di- and tripeptides that are transported amongst others to the joint. In addition to reducing cartilage degradation, CH metabolites may reduce synovial inflammation and subchondral bone sclerosis during OA. Preliminary evidence in dogs suffering from the consequences of OA support the clinical efficacy of CH with reported reductions in lameness. However, effects on biomarker level of cartilage metabolism and inflammation are inconclusive. Additionally, current studies show a lack of standardised dosing regimens and the use of not validated outcomes. Future work should therefore elucidate further on the bioavailability of CH in dogs in order to establish adequate dosing recommendations. Furthermore, high-quality placebo-controlled randomised controlled trials are essential to dstudies have evaluated the cetermine the clinical efficacy of CH to reduce lameness, prevent OA progression and thereby improve the level of evidence.
骨关节炎(OA)是犬类的一种常见疾病,对其健康有严重影响。OA的多模式管理包括喂食治疗性饮食和营养保健品以减缓OA进展。水解胶原蛋白(CH)是一种营养补充剂,可能对骨关节炎关节软骨产生合成代谢作用以及疾病修饰作用。口服后,CH主要以氨基酸、二肽和三肽的形式被吸收,这些物质会被运输到关节等部位。除了减少软骨降解外,CH代谢产物在OA期间可能还会减轻滑膜炎症和软骨下骨硬化。患有OA后果的犬类的初步证据支持CH的临床疗效,据报道其可减轻跛行。然而,对软骨代谢和炎症生物标志物水平的影响尚无定论。此外,目前的研究表明缺乏标准化的给药方案且使用的结果未经验证。因此,未来的工作应进一步阐明CH在犬类中的生物利用度,以便制定适当的给药建议。此外,高质量的安慰剂对照随机对照试验对于确定CH减轻跛行、预防OA进展从而提高证据水平的临床疗效至关重要。